BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010;56:392-406. [PMID: 20650361 DOI: 10.1016/j.jacc.2010.05.011] [Cited by in Crossref: 259] [Cited by in F6Publishing: 220] [Article Influence: 21.6] [Reference Citation Analysis]
Number Citing Articles
1 Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, Silver KH, Shin J, Ewald G, Farr MJ, Anwaruddin S, Plat F, Fisher SJ, AuWerter AT, Pastore JM, Aras R, Penn MS. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur Heart J 2015;36:2228-38. [PMID: 26056125 DOI: 10.1093/eurheartj/ehv254] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 15.3] [Reference Citation Analysis]
2 Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf 2014;6:47-54. [PMID: 24855390 DOI: 10.2147/DHPS.S43275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, Choy AMJ, Gandy S, George J, Khan F, Pearson ER, Houston JG, Struthers AD, Lang CC. Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care 2020;43:1356-9. [PMID: 32245746 DOI: 10.2337/dc19-2187] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
4 Lupón J, Sanders-van Wijk S, Januzzi JL, de Antonio M, Gaggin HK, Pfisterer M, Galán A, Shah R, Brunner-la Rocca H, Bayes-genis A. Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. International Journal of Cardiology 2016;204:242-7. [DOI: 10.1016/j.ijcard.2015.11.163] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
5 Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol 2014;63:1593-603. [PMID: 24530674 DOI: 10.1016/j.jacc.2014.01.014] [Cited by in Crossref: 160] [Cited by in F6Publishing: 152] [Article Influence: 20.0] [Reference Citation Analysis]
6 Stoll VM, Hess AT, Rodgers CT, Bissell MM, Dyverfeldt P, Ebbers T, Myerson SG, Carlhäll CJ, Neubauer S. Left Ventricular Flow Analysis. Circ Cardiovasc Imaging 2019;12:e008130. [PMID: 31109184 DOI: 10.1161/CIRCIMAGING.118.008130] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
7 Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, Stark MA, von Bardeleben RS, Cremer PC, Jaber WA, Celermajer DS, Kaye DM, Sievert H. The REDUCE FMR Trial: A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation. JACC Heart Fail 2019;7:945-55. [PMID: 31521683 DOI: 10.1016/j.jchf.2019.06.011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
8 Castelvecchio S, Moroni F, Menicanti L. The matter of reverse ventricular remodeling after acute myocardial infarction between fiction and reality. J Cardiovasc Med (Hagerstown) 2018;19:397-8. [PMID: 29952845 DOI: 10.2459/JCM.0000000000000658] [Reference Citation Analysis]
9 Costanzo MR, Ponikowski P, Coats A, Javaheri S, Augostini R, Goldberg LR, Holcomb R, Kao A, Khayat RN, Oldenburg O, Stellbrink C, McKane S, Abraham WT; remedē® System Pivotal Trial Study Group. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. Eur J Heart Fail 2018;20:1746-54. [PMID: 30303611 DOI: 10.1002/ejhf.1312] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
10 Goyal A, Krishnaswamy A. Percutaneous Valve Interventions in Heart Failure. Curr Treat Options Cardio Med 2020;22. [DOI: 10.1007/s11936-020-00841-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Matsumura Y, Hoshikawa-Nagai E, Kubo T, Yamasaki N, Kitaoka H, Takata J, Doi Y, Sugiura T. Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. Cardiovasc Ultrasound 2015;13:14. [PMID: 25880063 DOI: 10.1186/s12947-015-0009-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Sekaran NK, Crowley AL, de Souza FR, Resende ES, Rao SV. The Role for Cardiovascular Remodeling in Cardiovascular Outcomes. Curr Atheroscler Rep 2017;19. [DOI: 10.1007/s11883-017-0656-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
13 Gold MR, Van Veldhuisen DJ, Hauptman PJ, Borggrefe M, Kubo SH, Lieberman RA, Milasinovic G, Berman BJ, Djordjevic S, Neelagaru S, Schwartz PJ, Starling RC, Mann DL. Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology 2016;68:149-58. [DOI: 10.1016/j.jacc.2016.03.525] [Cited by in Crossref: 151] [Cited by in F6Publishing: 129] [Article Influence: 25.2] [Reference Citation Analysis]
14 Konstam MA. Ventricular remodelling: an equal-opportunity prognosticator. Eur J Heart Fail 2020;22:2269-71. [PMID: 32839983 DOI: 10.1002/ejhf.1991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, Dickstein K, Linde C, Vernooy K, Leyva F, Bauersachs J, Israel CW, Lund LH, Donal E, Boriani G, Jaarsma T, Berruezo A, Traykov V, Yousef Z, Kalarus Z, Nielsen JC, Steffel J, Vardas P, Coats A, Seferovic P, Edvardsen T, Heidbuchel H, Ruschitzka F, Leclercq C. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace 2021:euaa411. [PMID: 34037728 DOI: 10.1093/europace/euaa411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Lin SN, Phang KK, Toh SH, Chee KH, Zaman Huri H. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction. Front Endocrinol (Lausanne) 2020;11:448. [PMID: 32754118 DOI: 10.3389/fendo.2020.00448] [Reference Citation Analysis]
17 Udelson JE, Stevenson LW. The Future of Heart Failure Diagnosis, Therapy, and Management. Circulation 2016;133:2671-86. [DOI: 10.1161/circulationaha.116.023518] [Cited by in Crossref: 53] [Cited by in F6Publishing: 17] [Article Influence: 8.8] [Reference Citation Analysis]
18 Clerfond G, Bière L, Mateus V, Grall S, Willoteaux S, Prunier F, Furber A. End-systolic wall stress predicts post-discharge heart failure after acute myocardial infarction. Arch Cardiovasc Dis 2015;108:310-20. [PMID: 25858536 DOI: 10.1016/j.acvd.2015.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
19 Wessler BS, Kramer DG, Kelly JL, Trikalinos TA, Kent DM, Konstam MA, Udelson JE. Drug and Device Effects on Peak Oxygen Consumption, 6-Minute Walk Distance, and Natriuretic Peptides as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Circ: Heart Failure 2011;4:578-88. [DOI: 10.1161/circheartfailure.111.961573] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
20 Schmidt T, Frerker C, Thielsen T, Dotz I, Wohlmuth P, Kuck KH, Schäfer U. New evidence for favourable effects on haemodynamics and ventricular performance after Parachute(®) implantation in humans. Eur J Heart Fail 2014;16:1112-9. [PMID: 25298333 DOI: 10.1002/ejhf.160] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
21 Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 2021;8:754499. [PMID: 34859070 DOI: 10.3389/fcvm.2021.754499] [Reference Citation Analysis]
22 Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, Dickstein K, Linde C, Vernooy K, Leyva F, Bauersachs J, Israel CW, Lund LH, Donal E, Boriani G, Jaarsma T, Berruezo A, Traykov V, Yousef Z, Kalarus Z, Cosedis Nielsen J, Steffel J, Vardas P, Coats A, Seferovic P, Edvardsen T, Heidbuchel H, Ruschitzka F, Leclercq C. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail 2020;22:2349-69. [PMID: 33136300 DOI: 10.1002/ejhf.2046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
23 Konstam MA. Viability, Remodeling, and CABG. JACC: Cardiovascular Imaging 2015;8:1130-2. [DOI: 10.1016/j.jcmg.2015.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Paton MF, Gierula J, Lowry JE, Cairns DA, Bose Rosling K, Cole CA, McGinlay M, Straw S, Byrom R, Cubbon RM, Kearney MT, Witte KK. Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial. PLoS One 2021;16:e0259450. [PMID: 34898655 DOI: 10.1371/journal.pone.0259450] [Reference Citation Analysis]
25 Plump A, Madwed J. Heart failure drug discovery: Scarred or ready for remodeling? Journal of Molecular and Cellular Cardiology 2011;51:444-8. [DOI: 10.1016/j.yjmcc.2011.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, Smith PK, Hung JW, Blackstone EH, Puskas JD, Argenziano M, Gammie JS, Mack M, Ascheim DD, Bagiella E, Moquete EG, Ferguson TB, Horvath KA, Geller NL, Miller MA, Woo YJ, D'Alessandro DA, Ailawadi G, Dagenais F, Gardner TJ, O'Gara PT, Michler RE, Kron IL; CTSN. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2014;370:23-32. [PMID: 24245543 DOI: 10.1056/nejmoa1312808] [Cited by in Crossref: 552] [Cited by in F6Publishing: 130] [Article Influence: 61.3] [Reference Citation Analysis]
27 Frljak S, Poglajen G, Zemljic G, Cerar A, Haddad F, Terzic A, Vrtovec B. Larger End-Diastolic Volume Associates With Response to Cell Therapy in Patients With Nonischemic Dilated Cardiomyopathy. Mayo Clin Proc 2020;95:2125-33. [PMID: 33012343 DOI: 10.1016/j.mayocp.2020.02.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Papadimitriou L, Georgiopoulou VV, Kort S, Butler J, Kalogeropoulos AP. Echocardiography in Acute Heart Failure: Current Perspectives. Journal of Cardiac Failure 2016;22:82-94. [DOI: 10.1016/j.cardfail.2015.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
29 Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc 2019;8:e012272. [PMID: 31240976 DOI: 10.1161/JAHA.119.012272] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
30 Psotka MA, Teerlink JR. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. In: Bauersachs J, Butler J, Sandner P, editors. Heart Failure. Cham: Springer International Publishing; 2017. pp. 465-90. [DOI: 10.1007/164_2017_13] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
31 De Ferrari GM, Tuinenburg AE, Ruble S, Brugada J, Klein H, Butter C, Wright DJ, Schubert B, Solomon S, Meyer S. Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. Eur J Heart Fail. 2014;16:692-699. [PMID: 24846173 DOI: 10.1002/ejhf.80] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
32 He Y, Ling Y, Guo W, Li Q, Yu S, Huang H, Zhang R, Gong Z, Liu J, Mo L, Yi S, Lai D, Yao Y, Liu J, Chen J, Liu Y, Chen S. Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis. Front Cardiovasc Med 2021;8:757596. [PMID: 34901217 DOI: 10.3389/fcvm.2021.757596] [Reference Citation Analysis]
33 Gokhroo RK, Anushri K, Tarik MT, Kailash C, Rajesh N, Ashish K, Manish G, Subhash C. 1 year follow Up results of "ARTIM HF TRIAL" (angiotensin receptor neprilysin inhibitor effect on TEI index & left ventricular mass in heart failure). Indian Heart J 2021;73:205-10. [PMID: 33865519 DOI: 10.1016/j.ihj.2021.01.010] [Reference Citation Analysis]
34 Koshy AO, Swoboda PPP, Gierula J, Witte KK. Cardiac magnetic resonance in patients with cardiac resynchronization therapy: is it time to scan with resynchronization on? Europace 2019;21:554-62. [PMID: 30608530 DOI: 10.1093/europace/euy299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, Tsioufis K, Tousoulis D. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. Pharmacol Res 2022;:106243. [PMID: 35523389 DOI: 10.1016/j.phrs.2022.106243] [Reference Citation Analysis]
36 Biffi M, Loforte A, Folesani G, Ziacchi M, Attinà D, Niro F, Pasquale F, Pacini D. Hybrid transcatheter left ventricular reconstruction for the treatment of ischemic cardiomyopathy. Cardiovasc Diagn Ther 2021;11:183-92. [PMID: 33708491 DOI: 10.21037/cdt-20-265] [Reference Citation Analysis]
37 Kapur NK, Paruchuri V. Interventions for failing vessels, valves, and now … ventricles: the parachute device. Catheter Cardiovasc Interv 2014;83:631-2. [PMID: 24532330 DOI: 10.1002/ccd.25398] [Reference Citation Analysis]
38 Anand IS, Florea VG. Alterations in Ventricular Structure. Heart Failure: A Companion to Braunwald's Heart Disease. Elsevier; 2011. pp. 232-53. [DOI: 10.1016/b978-1-4160-5895-3.10015-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert J, Holzmeister J, Lam CS, Pochet T, Vincent A, Linde C. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction: CRT in HF patients with less severe LV dysfunction. Eur J Heart Fail 2015;17:135-43. [DOI: 10.1002/ejhf.208] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
40 van den Berge JC, Vroegindewey MM, Veenis JF, Brugts JJ, Caliskan K, Manintveld OC, Akkerhuis KM, Boersma E, Deckers JW, Constantinescu AA. Left ventricular remodelling and prognosis after discharge in new-onset acute heart failure with reduced ejection fraction. ESC Heart Fail 2021;8:2679-89. [PMID: 33934556 DOI: 10.1002/ehf2.13299] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Enzan N, Matsushima S, Ide T, Tohyama T, Funakoshi K, Higo T, Tsutsui H. The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin-converting enzyme inhibitor in dilated cardiomyopathy. ESC Heart Fail 2022. [PMID: 35137537 DOI: 10.1002/ehf2.13790] [Reference Citation Analysis]
42 Wessler BS, Udelson JE. Neuronal Dysfunction and Medical Therapy in Heart Failure: Can an Imaging Biomarker Help to “Personalize” Therapy? J Nucl Med 2015;56:20S-4S. [DOI: 10.2967/jnumed.114.142778] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
43 Duncan SE, Gao S, Sarhene M, Coffie JW, Linhua D, Bao X, Jing Z, Li S, Guo R, Su J, Fan G. Macrophage Activities in Myocardial Infarction and Heart Failure. Cardiol Res Pract 2020;2020:4375127. [PMID: 32377427 DOI: 10.1155/2020/4375127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
44 Daubert MA, Massaro J, Liao L, Pershad A, Mulukutla S, Magnus Ohman E, Popma J, O'Neill WW, Douglas PS. High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction. Am Heart J 2015;170:550-8. [PMID: 26385039 DOI: 10.1016/j.ahj.2015.06.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
45 Koopmans T, van Beijnum H, Roovers EF, Tomasso A, Malhotra D, Boeter J, Psathaki OE, Versteeg D, van Rooij E, Bartscherer K. Ischemic tolerance and cardiac repair in the spiny mouse (Acomys). NPJ Regen Med 2021;6:78. [PMID: 34789755 DOI: 10.1038/s41536-021-00188-2] [Reference Citation Analysis]
46 Mao S, Li X, Wang L, Yang PC, Zhang M. Rationale and Design of Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction (STAMP-REMODELING) Trial: A Randomized Controlled Study. Cardiovasc Drugs Ther 2015;29:535-42. [PMID: 26482376 DOI: 10.1007/s10557-015-6625-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
47 Jørgensen ME, Andersson C, Vasan RS, Køber L, Abdulla J. Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: A systematic review and meta-analyses. Eur J Prev Cardiol 2018;25:366-76. [PMID: 29313369 DOI: 10.1177/2047487317750437] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
48 Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. European Heart Journal 2011;32:1838-45. [DOI: 10.1093/eurheartj/ehr026] [Cited by in Crossref: 124] [Cited by in F6Publishing: 102] [Article Influence: 11.3] [Reference Citation Analysis]
49 Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60:1455-1469. [PMID: 22999723 DOI: 10.1016/j.jacc.2011.11.082] [Cited by in Crossref: 256] [Cited by in F6Publishing: 228] [Article Influence: 25.6] [Reference Citation Analysis]
50 Chouchoulis K, Chiladakis J, Koutsogiannis N, Davlouros P, Kaza M, Alexopoulos D. Impact of QT interval prolongation following antiarrhythmic drug therapy on left ventricular function. Future Cardiol 2017;13:13-22. [PMID: 27990843 DOI: 10.2217/fca-2016-0052] [Reference Citation Analysis]
51 Rao SV, Zeymer U, Douglas PS, Al-Khalidi H, White JA, Liu J, Levy H, Guetta V, Gibson CM, Tanguay JF, Vermeersch P, Roncalli J, Kasprzak JD, Henry TD, Frey N, Kracoff O, Traverse JH, Chew DP, Lopez-Sendon J, Heyrman R, Krucoff MW. Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. J Am Coll Cardiol 2016;68:715-23. [PMID: 27515331 DOI: 10.1016/j.jacc.2016.05.053] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
52 Kanefendt F, Thuß U, Becka M, Boxnick S, Berse M, Schultz A, Otto C. Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev 2019;8:467-79. [PMID: 29878583 DOI: 10.1002/cpdd.579] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
53 Armenian SH, Hudson MM, Chen MH, Colan SD, Lindenfeld L, Mills G, Siyahian A, Gelehrter S, Dang H, Hein W, Green DM, Robison LL, Wong FL, Douglas PS, Bhatia S. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. BMC Cardiovasc Disord 2016;16:187. [PMID: 27716152 DOI: 10.1186/s12872-016-0364-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
54 Song J, Frieler RA, Whitesall SE, Chung Y, Vigil TM, Muir LA, Ma J, Brombacher F, Goonewardena SN, Lumeng CN, Goldstein DR, Mortensen RM. Myeloid interleukin-4 receptor α is essential in postmyocardial infarction healing by regulating inflammation and fibrotic remodeling. Am J Physiol Heart Circ Physiol 2021;320:H323-37. [PMID: 33164548 DOI: 10.1152/ajpheart.00251.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Rodriguez-Palomares JF, Gavara J, Ferreira-González I, Valente F, Rios C, Rodríguez-García J, Bonanad C, García Del Blanco B, Miñana G, Mutuberria M, Nuñez J, Barrabés J, Evangelista A, Bodí V, García-Dorado D. Prognostic Value of Initial Left Ventricular Remodeling in Patients With Reperfused STEMI. JACC Cardiovasc Imaging 2019;12:2445-56. [PMID: 31202752 DOI: 10.1016/j.jcmg.2019.02.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
56 Bazoukis G, Naka KK, Alsheikh-Ali A, Tse G, Letsas KP, Korantzopoulos P, Liu T, Yeung C, Efremidis M, Tsioufis K, Baranchuk A, Stavrakis S. Association of QRS narrowing with response to cardiac resynchronization therapy-a systematic review and meta-analysis of observational studies. Heart Fail Rev 2020;25:745-56. [PMID: 31392534 DOI: 10.1007/s10741-019-09839-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
57 Zhang Q, Chan Y, Liang Y, Fang F, Lam Y, Chan C, Lee AP, Chan KC, Wu EB, Yu C. Comparison of left ventricular reverse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations. International Journal of Cardiology 2013;167:889-93. [DOI: 10.1016/j.ijcard.2012.01.066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
58 Tobler D, Bouchardy J, Reto E, Heg D, Müller C, Frenk A, Gabriel H, Schwitter J, Rutz T, Buechel RR, Willhelm M, Trachsel L, Freese M, Greutmann M, Schwerzmann M. Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function – A multi-center, double-blind, randomized, placebo-controlled clinical trial – SERVE trial - Rational and design. International Journal of Cardiology 2017;243:354-9. [DOI: 10.1016/j.ijcard.2017.05.079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
59 Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, Pearson ER, Struthers AD, Lang CC. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol 2016;15:97. [PMID: 27422625 DOI: 10.1186/s12933-016-0419-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
60 Lavine KJ, Mann DL. Rethinking Phase II Clinical Trial Design in Heart Failure. Clin Investig (Lond) 2013;3:57-68. [PMID: 25343020 DOI: 10.4155/cli.12.133] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
61 Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 2012;60:2465-72. [PMID: 23158527 DOI: 10.1016/j.jacc.2012.06.062] [Cited by in Crossref: 156] [Cited by in F6Publishing: 135] [Article Influence: 15.6] [Reference Citation Analysis]
62 Felker GM. Augmenting outcomes in patients with advanced heart failure. Eur Heart J 2015;36:2276-8. [DOI: 10.1093/eurheartj/ehv283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Januzzi JL Jr, Camacho A, Piña IL, Rocha R, Williamson KM, Maisel AS, Felker GM, Prescott MF, Butler J, Solomon SD; PROVE-HF Investigators. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. Circ Heart Fail 2020;13:e006946. [PMID: 32482089 DOI: 10.1161/CIRCHEARTFAILURE.119.006946] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
64 Basuray A, Fang JC. Heart Failure With a Better Ejection Fraction: Why Should We Care? Circ: Heart Failure 2016;9. [DOI: 10.1161/circheartfailure.116.003318] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 Zhu Z, Yu J, Xu K, Tang Y, Fang Y, Gu J, Gu S, Ding F, Modine T, Zhang R. First-in-man study of Heartech® percutaneous left ventricular partitioning device for treatment of heart failure postmyocardial infarction. Catheter Cardiovasc Interv 2019;94:845-53. [PMID: 31231944 DOI: 10.1002/ccd.28366] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S, Leor J, Perrino C, Schulz R, Ytrehus K, Landmesser U, Mummery CL, Janssens S, Willerson J, Eschenhagen T, Ferdinandy P, Sluijter JP. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J. 2016;37:1789-1798. [PMID: 27055812 DOI: 10.1093/eurheartj/ehw113] [Cited by in Crossref: 147] [Cited by in F6Publishing: 147] [Article Influence: 24.5] [Reference Citation Analysis]
67 Cokkinos DV, Belogianneas C. Left Ventricular Remodelling: A Problem in Search of Solutions. Eur Cardiol 2016;11:29-35. [PMID: 30310445 DOI: 10.15420/ecr.2015:9:3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
68 Kienemund J, Kuck KH, Frerker C. Cardiac Resynchronisation Therapy or MitraClip® Implantation for Patients with Severe Mitral Regurgitation and Left Bundle Branch Block? Arrhythm Electrophysiol Rev 2014;3:190-3. [PMID: 26835090 DOI: 10.15420/aer.2014.3.3.190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
69 Borlaug BA. Defining HFpEF: where do we draw the line? Eur Heart J 2016;37:463-5. [DOI: 10.1093/eurheartj/ehv561] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
70 Majka M, Sułkowski M, Badyra B, Musiałek P. Concise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical Applications. Stem Cells Transl Med 2017;6:1859-67. [PMID: 28836732 DOI: 10.1002/sctm.16-0484] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
71 Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M. Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. Circ Heart Fail 2017;10:e003800. [PMID: 28356300 DOI: 10.1161/CIRCHEARTFAILURE.116.003800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
72 Tanabe K, Sakamoto T. Heart failure with recovered ejection fraction. J Echocardiogr 2019;17:5-9. [PMID: 30218436 DOI: 10.1007/s12574-018-0396-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
73 Gold MR, Daubert C, Abraham WT, Ghio S, St John Sutton M, Hudnall JH, Cerkvenik J, Linde C. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm 2015;12:524-30. [PMID: 25460860 DOI: 10.1016/j.hrthm.2014.11.014] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
74 Kalogeropoulos AP, Georgiopoulou VV, Borlaug BA, Gheorghiade M, Butler J. Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research. Circ Heart Fail 2013;6:584-93. [PMID: 23694772 DOI: 10.1161/CIRCHEARTFAILURE.112.000096] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
75 Muller DW, Farivar RS, Jansz P, Bae R, Walters D, Clarke A, Grayburn PA, Stoler RC, Dahle G, Rein KA, Shaw M, Scalia GM, Guerrero M, Pearson P, Kapadia S, Gillinov M, Pichard A, Corso P, Popma J, Chuang M, Blanke P, Leipsic J, Sorajja P, Muller D, Jansz P, Shaw M, Conellan M, Spina R, Pedersen W, Sorajja P, Farivar RS, Bae R, Sun B, Walters D, Clarke A, Scalia G, Grayburn P, Stoler R, Hebeler R, Dahle G, Rein KA, Fiane A, Guerrero M, Pearson P, Feldman T, Salinger M, Smart S, Kapadia S, Gillinov M, Mick S, Krishnaswamy A, Pichard A, Corso P, Chuang M, Popma J, Leipsic J, Blanke P, Carroll J, George I, Missov E, Kiser A. Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation. Journal of the American College of Cardiology 2017;69:381-91. [DOI: 10.1016/j.jacc.2016.10.068] [Cited by in Crossref: 178] [Cited by in F6Publishing: 136] [Article Influence: 35.6] [Reference Citation Analysis]
76 Costanzo MR, Ivanhoe RJ, Kao A, Anand IS, Bank A, Boehmer J, Demarco T, Hergert CM, Holcomb RG, Maybaum S, Sun B, Vassiliades TA, Rayburn BK, Abraham WT. Prospective Evaluation of Elastic Restraint to Lessen the Effects of Heart Failure (PEERLESS-HF) Trial. Journal of Cardiac Failure 2012;18:446-58. [DOI: 10.1016/j.cardfail.2012.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
77 Marwick TH. Ejection Fraction Pros and Cons. Journal of the American College of Cardiology 2018;72:2360-79. [DOI: 10.1016/j.jacc.2018.08.2162] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 11.8] [Reference Citation Analysis]
78 Clark KAA, Velazquez EJ. Heart Failure With Preserved Ejection Fraction: Time for a Reset. JAMA 2020;324:1506-8. [PMID: 33079136 DOI: 10.1001/jama.2020.15566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
79 Chang HY, Chen KC, Fong MC, Feng AN, Fu HN, Huang KC, Chong E, Yin WH. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. J Cardiol 2020;75:233-41. [PMID: 31563433 DOI: 10.1016/j.jjcc.2019.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
80 Kandolin RM, Wiefels CC, Mesquita CT, Chong A, Boland P, Glineur D, Sun L, Beanlands RS, Mielniczuk LM. The Current Role of Viability Imaging to Guide Revascularization and Therapy Decisions in Patients With Heart Failure and Reduced Left Ventricular Function. Canadian Journal of Cardiology 2019;35:1015-29. [DOI: 10.1016/j.cjca.2019.04.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
81 Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, O'Connor C, Goldstein S, Udelson JE, Sabbah HN. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail 2017;10:e004389. [PMID: 29217757 DOI: 10.1161/CIRCHEARTFAILURE.117.004389] [Cited by in Crossref: 75] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
82 Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ; EMPA-TROPISM (ATRU-4) Investigators. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol 2021;77:243-55. [PMID: 33197559 DOI: 10.1016/j.jacc.2020.11.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
83 Shokry KA, Farag EM, Salem AM, Ibrahim IM, Abel-Aziz M, El Zayat A. Original Article--Value of Pathological Q Waves and Angiographic Collateral Grade in Patients Undergoing Coronary Chronic Total Occlusion Recanalization: Cardiac Magnetic Resonance Study. J Saudi Heart Assoc 2021;33:41-50. [PMID: 33880327 DOI: 10.37616/2212-5043.1239] [Reference Citation Analysis]
84 Díez-lópez C, Salazar-mendiguchía J, García-romero E, Fuentes L, Lupón J, Bayés-genis A, Manito N, de Antonio M, Moliner P, Zamora E, Catalá-ruiz P, Caínzos-achirica M, Comín-colet J, González-costello J. Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy. JCDD 2022;9:20. [DOI: 10.3390/jcdd9010020] [Reference Citation Analysis]
85 Banovic M, Loncar Z, Behfar A, Vanderheyden M, Beleslin B, Zeiher A, Metra M, Terzic A, Bartunek J. Endpoints in stem cell trials in ischemic heart failure. Stem Cell Res Ther. 2015;6:159. [PMID: 26319401 DOI: 10.1186/s13287-015-0143-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
86 Forsyth P, Moir L, Speirits I, McGlynn S, Ryan M, Watson A, Reid F, Rush C, Murphy C. Improving medication optimisation in left ventricular systolic dysfunction after acute myocardial infarction. BMJ Open Qual 2019;8:e000676. [PMID: 31544164 DOI: 10.1136/bmjoq-2019-000676] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
87 DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J, Patterson JH, Spertus JA, Williams FB, Duffy CI, Hernandez AF, Fonarow GC. Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. Circ Heart Fail 2020;13:e006833. [PMID: 32580657 DOI: 10.1161/CIRCHEARTFAILURE.119.006833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Tourki B, Dumesnil A, Belaidi E, Ghrir S, Godin-Ribuot D, Marrakchi N, Richard V, Mulder P, Messadi E. Lebetin 2, a Snake Venom-Derived B-Type Natriuretic Peptide, Provides Immediate and Prolonged Protection against Myocardial Ischemia-Reperfusion Injury via Modulation of Post-Ischemic Inflammatory Response. Toxins (Basel) 2019;11:E524. [PMID: 31510060 DOI: 10.3390/toxins11090524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011;161:915.e1-9. [PMID: 21570522 DOI: 10.1016/j.ahj.2011.02.011] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 6.6] [Reference Citation Analysis]
90 Walker MJ. The major impacts of James Black's drug discoveries on medicine and pharmacology. Trends in Pharmacological Sciences 2011;32:183-8. [DOI: 10.1016/j.tips.2011.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
91 Docherty KF, Campbell RT, Brooksbank KJM, Dreisbach JG, Forsyth P, Godeseth RL, Hopkins T, Jackson AM, Lee MMY, McConnachie A, Roditi G, Squire IB, Stanley B, Welsh P, Jhund PS, Petrie MC, McMurray JJV. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation 2021;144:199-209. [PMID: 33983794 DOI: 10.1161/CIRCULATIONAHA.121.054892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Duengen HD, Kim RJ, Zahger D, Orvin K, Kornowski R, Admon D, Kettner J, Shimony A, Otto C, Becka M, Kanefendt F, Romo AI, Hasin T, Ostadal P, Rojas GC, Senni M; GROUP investigators of the CHIARA MIA 2 trial. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. Am Heart J 2020;224:129-37. [PMID: 32375104 DOI: 10.1016/j.ahj.2020.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Rozman J, Perme MP, Jez M, Malicev E, Krasna M, Novakovic S, Vrtovec B, Rozman P. The effect of CD34 + cell telomere length and hTERT expression on the outcome of autologous CD34 + cell transplantation in patients with chronic heart failure. Mechanisms of Ageing and Development 2017;166:42-7. [DOI: 10.1016/j.mad.2017.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Straw S, McGinlay M, Gierula J, Lowry JE, Paton MF, Cole C, Drozd M, Koshy AO, Mullens W, Cubbon RM, Kearney MT, Witte KK. Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. J Cardiovasc Med (Hagerstown) 2021;22:848-56. [PMID: 34261079 DOI: 10.2459/JCM.0000000000001231] [Reference Citation Analysis]
95 Zacà V, Murphy T, Biffi M. Electrical manipulation of the failing heart. Heart Fail Rev 2018;23:885-96. [DOI: 10.1007/s10741-018-9732-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Tajes M, Díez-López C, Enjuanes C, Moliner P, Ferreiro JL, Garay A, Jiménez-Marrero S, Yun S, Sosa SG, Alcoberro L, González-Costello J, García-Romero E, Yañez-Bisbe L, Benito B, Comín-Colet J. Neurohormonal activation induces intracellular iron deficiency and mitochondrial dysfunction in cardiac cells. Cell Biosci 2021;11:89. [PMID: 34001233 DOI: 10.1186/s13578-021-00605-5] [Reference Citation Analysis]
97 Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol 2012;60:2305-12. [PMID: 23122795 DOI: 10.1016/j.jacc.2012.07.056] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
98 Lustosa RP, van der Bijl P, El Mahdiui M, Montero-Cabezas JM, Kostyukevich MV, Ajmone Marsan N, Bax JJ, Delgado V. Noninvasive Myocardial Work Indices 3 Months after ST-Segment Elevation Myocardial Infarction: Prevalence and Characteristics of Patients with Postinfarction Cardiac Remodeling. J Am Soc Echocardiogr 2020;33:1172-9. [PMID: 32651125 DOI: 10.1016/j.echo.2020.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Docherty KF, Vaduganathan M. OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failure. Eur J Heart Fail 2021;23:136-9. [PMID: 33480140 DOI: 10.1002/ejhf.2106] [Reference Citation Analysis]
100 Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014;129:2380-7. [PMID: 24799515 DOI: 10.1161/CIRCULATIONAHA.113.006855] [Cited by in Crossref: 146] [Cited by in F6Publishing: 59] [Article Influence: 18.3] [Reference Citation Analysis]
101 Pinar AA, Scott TE, Huuskes BM, Tapia Cáceres FE, Kemp-harper BK, Samuel CS. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacology & Therapeutics 2020;209:107511. [DOI: 10.1016/j.pharmthera.2020.107511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
102 Kiernan MS, Konstam MA. Moderate renal insufficiency does not attenuate the clinical benefit of aldosterone antagonists in heart failure. J Am Coll Cardiol 2012;60:2090-1. [PMID: 23083776 DOI: 10.1016/j.jacc.2012.08.971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Padmanabhan A, Haldar SM. Plasma MicroRNA Clusters in Human Left Ventricular Remodeling: A Biomarker and Discovery Platform. Circ Heart Fail 2018;11:e004793. [PMID: 29438983 DOI: 10.1161/CIRCHEARTFAILURE.117.004793] [Reference Citation Analysis]
104 Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, Abbate A. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 2011;108:19725-30. [PMID: 22106299 DOI: 10.1073/pnas.1108586108] [Cited by in Crossref: 347] [Cited by in F6Publishing: 334] [Article Influence: 31.5] [Reference Citation Analysis]
105 Rao SV, Zeymer U, Douglas PS, Al-Khalidi H, Liu J, Gibson CM, Harrison RW, Joseph DS, Heyrman R, Krucoff MW. A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. Am Heart J 2015;170:929-37. [PMID: 26542501 DOI: 10.1016/j.ahj.2015.08.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
106 Gimelli A, Lancellotti P, Badano LP, Lombardi M, Gerber B, Plein S, Neglia D, Edvardsen T, Kitsiou A, Scholte AJHA, Schroder S, Cosyns B, Gargiulo P, Zamorano JL, Perrone-filardi P. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). European Heart Journal 2014;35:3417-25. [DOI: 10.1093/eurheartj/ehu433] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
107 Wessler BS, McCauley M, Morine K, Konstam MA, Udelson JE. Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 2019;21:613-20. [PMID: 30919541 DOI: 10.1002/ejhf.1411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
108 Huang H, Liu J, Lei M, Yang Z, Bao K, Li Q, Lai W, Wang B, He Y, Chen S, Ou CQ, Abudukerimu M, Hu Y, Tan N, Chen J, Liu Y. A Universal New Definition of Heart Failure With Improved Ejection Fraction for Patients With Coronary Artery Disease. Front Physiol 2021;12:770650. [PMID: 34925066 DOI: 10.3389/fphys.2021.770650] [Reference Citation Analysis]
109 Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo JA, Velazquez EJ, Daubert JP. Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block. J Am Coll Cardiol 2018;71:306-17. [PMID: 29348023 DOI: 10.1016/j.jacc.2017.11.020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
110 Shah P, Psotka M, Taleb I, Alharethi R, Shams MA, Wever-Pinzon O, Yin M, Latta F, Stehlik J, Fang JC, Diao G, Singh R, Ijaz N, Kyriakopoulos CP, Zhu W, May CW, Cooper LB, Desai SS, Selzman CH, Kfoury AG, Drakos SG. Framework to Classify Reverse Cardiac Remodeling With Mechanical Circulatory Support: The Utah-Inova Stages. Circ Heart Fail 2021;14:e007991. [PMID: 33947201 DOI: 10.1161/CIRCHEARTFAILURE.120.007991] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Patel RB, Vaduganathan M, Samman-Tahhan A, Kalogeropoulos AP, Georgiopoulou VV, Fonarow GC, Gheorghiade M, Butler J. Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. Am J Cardiol 2016;117:1845-50. [PMID: 27085935 DOI: 10.1016/j.amjcard.2016.03.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
112 Albert J, Lezius S, Störk S, Morbach C, Güder G, Frantz S, Wegscheider K, Ertl G, Angermann CE. Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes. J Am Heart Assoc 2021;10:e017822. [PMID: 33496189 DOI: 10.1161/JAHA.120.017822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Daubert MA, White JA, Al-Khalidi HR, Velazquez EJ, Rao SV, Crowley AL, Zeymer U, Kasprzak JD, Guetta V, Krucoff MW, Douglas PS. Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. Am Heart J 2020;223:87-97. [PMID: 32203684 DOI: 10.1016/j.ahj.2020.02.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
114 Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2019;7:782-94. [PMID: 31401101 DOI: 10.1016/j.jchf.2019.06.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
115 Nijst P, Martens P, Dauw J, Tang WW, Bertrand PB, Penders J, Bruckers L, Voros G, Willems R, Vandervoort PM, Dupont M, Mullens W. Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy. Journal of the American College of Cardiology 2020;75:1426-38. [DOI: 10.1016/j.jacc.2020.01.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
116 Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, Norris C, Cooper L, Leifer E, Desvigne-Nickens P, Anstrom K, Fiuzat M, Ezekowitz J, Mark DB, O'Connor CM, Januzzi J, Felker GM. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. JACC Heart Fail 2019;7:158-68. [PMID: 30611722 DOI: 10.1016/j.jchf.2018.10.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
117 Kewcharoen J, Trongtorsak A, Thangjui S, Kanitsoraphan C, Prasitlumkum N. Female Gender Is Associated with an Increased Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure with Reduced Ejection Fraction. Medical Sciences 2022;10:21. [DOI: 10.3390/medsci10020021] [Reference Citation Analysis]
118 Lewey J, Levine LD, Elovitz MA, Irizarry OC, Arany Z. Importance of Early Diagnosis in Peripartum Cardiomyopathy. Hypertension 2020;75:91-7. [PMID: 31707840 DOI: 10.1161/HYPERTENSIONAHA.119.13291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
119 Liu X, Yang HJ, Ping HQ, Qiu S, Shi S, Yang B. The safety and efficacy of cardiac contractility modulation in heart failure: A meta-analysis of clinical trials. Herz 2017;42:766-75. [DOI: 10.1007/s00059-016-4514-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
120 Chen K, Guan Y, Ma Y, Quan D, Zhang J, Liu X, Wu S, Lv L, Zhang G. Modulation of transforming growth factor-beta signaling pathway mediates the effects of Kangxian Formula on cardiac remodeling. J Ethnopharmacol 2021;272:113922. [PMID: 33588010 DOI: 10.1016/j.jep.2021.113922] [Reference Citation Analysis]
121 Xie X, Wu B, Chen Y, Li W, Hu X, Chen J. Peripheral endothelial function may predict the effectiveness of beta-blocker therapy in patients with idiopathic dilated cardiomyopathy. Int J Cardiol 2016;221:128-33. [PMID: 27400309 DOI: 10.1016/j.ijcard.2016.06.164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 2021. [PMID: 34489589 DOI: 10.1038/s41569-021-00605-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
123 Udelson JE, Konstam MA. Ventricular Remodeling. Journal of the American College of Cardiology 2011;57:1477-9. [DOI: 10.1016/j.jacc.2011.01.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
124 Docherty KF, Campbell RT, Brooksbank KJM, Godeseth RL, Forsyth P, McConnachie A, Roditi G, Stanley B, Welsh P, Jhund PS, Petrie MC, McMurray JJV. Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Fail 2021;8:129-38. [PMID: 33305513 DOI: 10.1002/ehf2.13137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Haddad F, Sever M, Poglajen G, Lezaic L, Yang P, Maecker H, Davis M, Kuznetsova T, Wu JC, Vrtovec B. Immunologic Network and Response to Intramyocardial CD34+ Stem Cell Therapy in Patients With Dilated Cardiomyopathy. J Card Fail 2015;21:572-82. [PMID: 25863169 DOI: 10.1016/j.cardfail.2015.03.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
126 Jaiswal A, Nguyen VQ, Carry BJ, le Jemtel TH. Pharmacologic and Endovascular Reversal of Left Ventricular Remodeling. Journal of Cardiac Failure 2016;22:829-39. [DOI: 10.1016/j.cardfail.2016.03.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
127 Hendriks T, Schurer RAJ, Al Ali L, van den Heuvel AFM, van der Harst P. Left ventricular restoration devices post myocardial infarction. Heart Fail Rev 2018;23:871-83. [PMID: 29770903 DOI: 10.1007/s10741-018-9711-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
128 Poglajen G, Ksela J, Frljak S, Zemljic G, Boznar Alic E, Cerar A, Vrtovec B. Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure. Dis Markers 2019;2019:8636930. [PMID: 31885743 DOI: 10.1155/2019/8636930] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD. A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. Circ Res. 2015;117:576-584. [PMID: 26148930 DOI: 10.1161/circresaha.115.306332] [Cited by in Crossref: 130] [Cited by in F6Publishing: 76] [Article Influence: 18.6] [Reference Citation Analysis]
130 Banerjee MN, Bolli R, Hare JM. Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions. Circ Res 2018;123:266-87. [PMID: 29976692 DOI: 10.1161/CIRCRESAHA.118.311217] [Cited by in Crossref: 71] [Cited by in F6Publishing: 43] [Article Influence: 23.7] [Reference Citation Analysis]
131 Kuttab JS, Kiernan MS, Vest AR. Epidemiology of “Heart Failure with Recovered Ejection Fraction”: What do we do After Recovery? Curr Heart Fail Rep 2015;12:360-6. [DOI: 10.1007/s11897-015-0274-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
132 Rickard J, Marine JE. Do smaller hearts live longer? The significance of reverse ventricular remodeling for long-term outcomes with cardiac resynchronization therapy. Heart Rhythm 2015;12:531-2. [PMID: 25485780 DOI: 10.1016/j.hrthm.2014.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
133 Lowry JE, Fichtlscherer S, Witte KK. Therapeutic options for functional mitral regurgitation in chronic heart failure. Expert Rev Med Devices 2018;15:357-65. [PMID: 29724138 DOI: 10.1080/17434440.2018.1473032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Mann DL, Felker GM. Mechanisms and Models in Heart Failure: A Translational Approach. Circ Res 2021;128:1435-50. [PMID: 33983832 DOI: 10.1161/CIRCRESAHA.121.318158] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Chandrasekaran U, Burkhoff D, Ishikawa K, Swain L, Sunagawa K, Møller J, Santos-Gallego C, Annamalai S, Udelson J, Westenfeld R, Kapur N, Qiao X, Wiora J, Schäfer A, Bernhardt A, Kochar A, Kloner R, Faraz H. Proceedings of the 3rd annual Acute Cardiac Unloading and REcovery (A-CURE) symposium. BMC Cardiovasc Disord 2019;19:27. [PMID: 30732562 DOI: 10.1186/s12872-019-1000-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
136 Nijst P, Martens P, Mullens W. Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next? Prog Cardiovasc Dis 2017;60:226-36. [PMID: 28551473 DOI: 10.1016/j.pcad.2017.05.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
137 Shi FH, Li H, Shen L, Xu L, Ge H, Gu ZC, Lin HW, Pu J. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function. J Clin Endocrinol Metab 2021:dgab834. [PMID: 34791312 DOI: 10.1210/clinem/dgab834] [Reference Citation Analysis]
138 Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovasc Drugs Ther 2019;33:87-95. [PMID: 30675708 DOI: 10.1007/s10557-018-06850-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
139 Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, Oskouei B, Byrnes J, Soto V, Tracy M, Zambrano JP, Heldman AW, Hare JM. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J 2011;161:487-93. [PMID: 21392602 DOI: 10.1016/j.ahj.2010.11.024] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 9.6] [Reference Citation Analysis]
140 El-Shurafa H, Albabtain M, Arafat A, Abdulsalam W, Alfonso J, Ashmeik K, Shah A, AlOtaiby M. Outcomes after Transcatheter Mitral Valve Edge to Edge Repair; a Comparison of Two Pathologies. Acta Cardiol Sin 2021;37:286-95. [PMID: 33976512 DOI: 10.6515/ACS.202105_37(3).20201020A] [Reference Citation Analysis]
141 Basuray A, Fang JC. Management of Patients With Recovered Systolic Function. Prog Cardiovasc Dis 2016;58:434-43. [PMID: 26796969 DOI: 10.1016/j.pcad.2016.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
142 Pokorney SD, Al-Khatib SM. Management of pace-terminated ventricular arrhythmias. Card Electrophysiol Clin 2015;7:497-513. [PMID: 26304530 DOI: 10.1016/j.ccep.2015.05.009] [Reference Citation Analysis]
143 Mullens W, Nijst P. Leadless Left Ventricular Pacing: Another Step Toward Improved CRT Response. J Am Coll Cardiol 2017;69:2130-3. [PMID: 28449773 DOI: 10.1016/j.jacc.2017.03.534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
144 Lipiecki J, Fahrat H, Monzy S, Caillot N, Siminiak T, Johnson T, Vogt S, Stark MA, Goldberg SL. Long-term prognosis of patients treated by coronary sinus-based percutaneous annuloplasty: single centre experience. ESC Heart Fail 2020. [PMID: 33047896 DOI: 10.1002/ehf2.12955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Grayburn PA, Packer M, Sannino A, Stone GW. Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications. Heart 2020:heartjnl-2020-316992. [PMID: 33234674 DOI: 10.1136/heartjnl-2020-316992] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
146 Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, Gottdiener J, Haluska B, Ofili E, Segers P, Senior R, Tapp RJ, Zamorano JL. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr 2015;28:727-54. [PMID: 26140936 DOI: 10.1016/j.echo.2015.05.002] [Cited by in Crossref: 169] [Cited by in F6Publishing: 135] [Article Influence: 28.2] [Reference Citation Analysis]
147 Ferrin PC, Mccreath L, Navankasattusas S, Drakos SG. Recovery Versus Remission. Heart Failure Clinics 2016;12:449-59. [DOI: 10.1016/j.hfc.2016.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
148 Correale M, Mallardi A, Mazzeo P, Tricarico L, Diella C, Romano V, Ferraretti A, Leopizzi A, Merolla G, Di Biase M, Brunetti ND. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry. Int J Cardiol Heart Vasc 2020;27:100486. [PMID: 32140553 DOI: 10.1016/j.ijcha.2020.100486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
149 Yazaki K, Ejima K, Kataoka S, Higuchi S, Kanai M, Yagishita D, Shoda M, Hagiwara N. Prognostic Significance of Post-Procedural Left Ventricular Ejection Fraction Following Atrial Fibrillation Ablation in Patients With Systolic Dysfunction. Circ Rep 2020;2:707-14. [PMID: 33693200 DOI: 10.1253/circrep.CR-20-0111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev 2021;26:623-42. [PMID: 33274396 DOI: 10.1007/s10741-020-10038-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
151 Daubert MA, Whellan DJ, Woehrle H, Tasissa G, Anstrom KJ, Lindenfeld J, Benjafield A, Blase A, Punjabi N, Fiuzat M, Oldenburg O, O'Connor CM. Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. Am Heart J 2018;201:40-8. [PMID: 29910054 DOI: 10.1016/j.ahj.2018.03.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
152 Hori M, Nagai R, Izumi T, Matsuzaki M. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessels. 2014;29:238-247. [PMID: 23559359 DOI: 10.1007/s00380-013-0340-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
153 Žorž N, Poglajen G, Frljak S, Knezevič I, Vrtovec B. Transendocardial CD34+ Cell Therapy Improves Local Mechanical Dyssynchrony in Patients With Nonischemic Dilated Cardiomyopathy. Cell Transplant 2022;31:9636897221080384. [PMID: 35320035 DOI: 10.1177/09636897221080384] [Reference Citation Analysis]
154 Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM; ATOMIC-AHF Investigators. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol 2016;67:1444-55. [PMID: 27012405 DOI: 10.1016/j.jacc.2016.01.031] [Cited by in Crossref: 125] [Cited by in F6Publishing: 108] [Article Influence: 20.8] [Reference Citation Analysis]
155 Zile MR, Gaasch WH, Patel K, Aban IB, Ahmed A. Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality. JACC Heart Fail 2014;2:512-22. [PMID: 25194295 DOI: 10.1016/j.jchf.2014.03.016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
156 Choi HM, Shin MS. Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence. Korean J Intern Med 2020;35:498-513. [PMID: 32392658 DOI: 10.3904/kjim.2020.105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
157 Bath AS, Raja J, Maturana MA, Khouzam RN. Complex interventions in the failing heart. Curr Opin Organ Transplant 2021;26:267-72. [PMID: 33938462 DOI: 10.1097/MOT.0000000000000877] [Reference Citation Analysis]
158 Hnat T, Veselka J, Honek J. Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy. ESC Heart Fail 2022. [PMID: 35437948 DOI: 10.1002/ehf2.13939] [Reference Citation Analysis]
159 Gombozhapova A, Rogovskaya Y, Shurupov V, Rebenkova M, Kzhyshkowska J, Popov SV, Karpov RS, Ryabov V. Macrophage activation and polarization in post-infarction cardiac remodeling. J Biomed Sci 2017;24:13. [PMID: 28173864 DOI: 10.1186/s12929-017-0322-3] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 14.0] [Reference Citation Analysis]
160 Drazner MH. Angiotensin Receptor-Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction. JAMA 2019;322:1051-3. [PMID: 31475298 DOI: 10.1001/jama.2019.12662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
161 Peixoto R, Pereira ML, Oliveira M. Beta-Blockers and Cancer: Where Are We? Pharmaceuticals (Basel) 2020;13:E105. [PMID: 32466499 DOI: 10.3390/ph13060105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
162 Fabijanovic D, Milicic D, Cikes M. Left Ventricular Size and Ejection Fraction. Heart Failure Clinics 2019;15:147-58. [DOI: 10.1016/j.hfc.2018.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
163 Kyriakopoulos CP, Kapelios CJ, Stauder EL, Taleb I, Hamouche R, Sideris K, Koliopoulou AG, Bonios MJ, Drakos SG. LVAD as a Bridge to Remission from Advanced Heart Failure: Current Data and Opportunities for Improvement. J Clin Med 2022;11:3542. [PMID: 35743611 DOI: 10.3390/jcm11123542] [Reference Citation Analysis]
164 Kontogiannis CD, Malliaras K, Kapelios CJ, Mason JW, Nanas JN. Continuous internal counterpulsation as a bridge to recovery in acute and chronic heart failure. World J Transplant 2016; 6(1): 115-124 [PMID: 27011909 DOI: 10.5500/wjt.v6.i1.115] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
165 Jacob MS, Tang WH. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr Heart Fail Rep 2011;8:7-13. [PMID: 21207206 DOI: 10.1007/s11897-010-0046-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
166 Maitz TN, Gupta R, Persin K, Sundlof DW. Utilization of sacubitril-valsartan for right ventricular failure in a patient with arrhythmogenic right ventricular cardiomyopathy. Future Cardiol 2022. [PMID: 35703395 DOI: 10.2217/fca-2021-0148] [Reference Citation Analysis]
167 Linde C, Braunschweig F. Cardiomyopathy and Left Bundle Branch Block. Journal of the American College of Cardiology 2018;71:318-20. [DOI: 10.1016/j.jacc.2017.11.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
168 Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, Merkely B, Musialek P, Wojakowski W, Andreka P, Horvath IG, Katz A, Dolatabadi D, El Nakadi B, Arandjelovic A, Edes I, Seferovic PM, Obradovic S, Vanderheyden M, Jagic N, Petrov I, Atar S, Halabi M, Gelev VL, Shochat MK, Kasprzak JD, Sanz-Ruiz R, Heyndrickx GR, Nyolczas N, Legrand V, Guédès A, Heyse A, Moccetti T, Fernandez-Aviles F, Jimenez-Quevedo P, Bayes-Genis A, Hernandez-Garcia JM, Ribichini F, Gruchala M, Waldman SA, Teerlink JR, Gersh BJ, Povsic TJ, Henry TD, Metra M, Hajjar RJ, Tendera M, Behfar A, Alexandre B, Seron A, Stough WG, Sherman W, Cotter G, Wijns W; CHART Program. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J 2017;38:648-60. [PMID: 28025189 DOI: 10.1093/eurheartj/ehw543] [Cited by in Crossref: 25] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
169 Draper TS Jr, Silver JS, Gaasch WH. Adverse structural remodeling of the left ventricle and ventricular arrhythmias in patients with depressed ejection fraction. J Card Fail 2015;21:97-102. [PMID: 25463741 DOI: 10.1016/j.cardfail.2014.10.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
170 Howard T, Spilias N, Bhattacharya S, Harb S, Puri R. Novel devices for managing heart failure. Curr Opin Cardiol 2022;37:261-71. [PMID: 35612938 DOI: 10.1097/HCO.0000000000000965] [Reference Citation Analysis]
171 Chen Y, Hsing S, Chao Y, Cheng Y, Lin C, Lin C, Fang W. Clinical Relevance of the LVEDD and LVESD Trajectories in HF Patients With LVEF < 35%. Front Med 2022;9:846361. [DOI: 10.3389/fmed.2022.846361] [Reference Citation Analysis]
172 Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011;58:1733-40. [PMID: 21996383 DOI: 10.1016/j.jacc.2011.07.022] [Cited by in Crossref: 238] [Cited by in F6Publishing: 192] [Article Influence: 21.6] [Reference Citation Analysis]
173 Moroni F, Castelvecchio S, Menicanti L. Reshaping the failing heart: One step forward in elucidating the role of biomaterials in preventing cardiac remodeling. Int J Cardiol 2018;255:152-3. [PMID: 29425554 DOI: 10.1016/j.ijcard.2017.12.072] [Reference Citation Analysis]
174 Greene SJ, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, O'Connor CM. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation 2018;138:1039-53. [PMID: 30354535 DOI: 10.1161/CIRCULATIONAHA.118.034668] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
175 Russo JJ, Prasad M, Doshi D, Karmpaliotis D, Parikh MA, Ali ZA, Popma JJ, Pershad A, Ohman EM, Douglas PS, O'neill WW, Leon MB, Moses JW, Kirtane AJ. Improvement in left ventricular function following higher‐risk percutaneous coronary intervention in patients with ischemic cardiomyopathy. Catheter Cardiovasc Interv 2020;96:764-70. [DOI: 10.1002/ccd.28557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K, Higo T, Tsutsui H. Beta-Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy. J Am Heart Assoc 2021;10:e019240. [PMID: 34053244 DOI: 10.1161/JAHA.120.019240] [Reference Citation Analysis]
177 Brener MI, Uriel N, Burkhoff D. Left Ventricular Volume Reduction and Reshaping as a Treatment Option for Heart Failure. Structural Heart 2020;4:264-83. [DOI: 10.1080/24748706.2020.1777359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
178 Cicoira M, Rossi A, Chiampan A, Frigo G, Bergamini C, Rigolli M, Zanolla L, Vassanelli C. Identification of high-risk chronic heart failure patients in clinical practice: role of changes in left ventricular function. Clin Cardiol 2012;35:580-4. [PMID: 22707317 DOI: 10.1002/clc.22024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
179 Bozdag-turan I, Bermaoui B, Turan RG, Kische S, Paranskaya L, Kloker K, Ortak J, Akin I, Hauenstein K, Nienaber CA, Ince H. Parachute Implant: CT Morphological Criteria of our Center to Identify the Suitable Patient. Cardiovasc Ther 2014;32:26-31. [DOI: 10.1111/1755-5922.12055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
180 Teerlink JR, Metra M, Filippatos GS, Davison BA, Bartunek J, Terzic A, Gersh BJ, Povsic TJ, Henry TD, Alexandre B, Homsy C, Edwards C, Seron A, Wijns W, Cotter G;  CHART Investigators. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. Eur J Heart Fail. 2017;19:1520-1529. [PMID: 28560782 DOI: 10.1002/ejhf.898] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 12.2] [Reference Citation Analysis]
181 Senni M, Gavazzi A, Gheorghiade M, Butler J. Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. Eur J Heart Fail 2015;17:760-3. [PMID: 26179815 DOI: 10.1002/ejhf.315] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
182 Pozo E, Sanz J. Técnicas de imagen en la evaluación de la función y cicatriz tras el infarto. Revista Española de Cardiología 2014;67:754-64. [DOI: 10.1016/j.recesp.2014.04.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
183 Bax JJ, Di Carli M, Narula J, Delgado V. Multimodality imaging in ischaemic heart failure. Lancet 2019;393:1056-70. [PMID: 30860031 DOI: 10.1016/S0140-6736(18)33207-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
184 Matsumura Y, Hoshikawa-Nagai E, Kubo T, Yamasaki N, Furuno T, Kitaoka H, Takata J, Sugiura T, Doi Y. Left ventricular reverse remodeling in long-term (>12 years) survivors with idiopathic dilated cardiomyopathy. Am J Cardiol 2013;111:106-10. [PMID: 23040590 DOI: 10.1016/j.amjcard.2012.08.056] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
185 Singh JP, Abraham WT, Auricchio A, Delnoy PP, Gold M, Reddy VY, Sanders P, Lindenfeld J, Rinaldi CA. Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. Am Heart J 2019;217:13-22. [PMID: 31472360 DOI: 10.1016/j.ahj.2019.04.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
186 Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart 2018;104:971-7. [DOI: 10.1136/heartjnl-2017-312103] [Cited by in Crossref: 128] [Cited by in F6Publishing: 108] [Article Influence: 25.6] [Reference Citation Analysis]
187 Fonseca C. Reverse remodeling: Much room for research. Rev Port Cardiol 2016;35:261-4. [PMID: 27173744 DOI: 10.1016/j.repc.2016.04.001] [Reference Citation Analysis]
188 Konstam MA. Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction. Eur J Heart Fail 2018;20:1240-2. [PMID: 29851266 DOI: 10.1002/ejhf.1205] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
189 Nabeta T, Inomata T, Ishii S, Yazaki M, Fujita T, Iida Y, Ikeda Y, Maekawa E, Naruke T, Koitabashi T, Ako J. Dilated cardiomyopathy with re-worsening left ventricular ejection fraction. Heart Vessels 2019;34:95-103. [PMID: 29942977 DOI: 10.1007/s00380-018-1214-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
190 Strange G, Playford D, Scalia GM, Celermajer DS, Prior D, Codde J, Chan YK, Bulsara MK, Stewart S; NEDA Investigators. Change in ejection fraction and long-term mortality in adults referred for echocardiography. Eur J Heart Fail 2021;23:555-63. [PMID: 33768605 DOI: 10.1002/ejhf.2161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Li J, Liu H, Liu Q, Liu C, Xiong W, Ma W, Zhang B, Dong S, Li T. Long-term prognosis analysis of PARACHUTE device implantation in patients with ischemic heart failure: a single-center experience of Chinese patients. J Cardiothorac Surg 2021;16:98. [PMID: 33879206 DOI: 10.1186/s13019-021-01484-0] [Reference Citation Analysis]
192 Mao S, Taylor S, Chen Q, Zhang M, Hinek A. Sodium tanshinone IIA sulfonate prevents the adverse left ventricular remodelling: Focus on polymorphonuclear neutrophil-derived granule components. J Cell Mol Med 2019;23:4592-600. [PMID: 31066232 DOI: 10.1111/jcmm.14306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
193 Saraon T, Katz SD. Reverse Remodeling in Systolic Heart Failure. Cardiology in Review 2015;23:173-81. [DOI: 10.1097/crd.0000000000000068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
194 Zhu Z, Zhu J, Yu J, Xu K, Tang Y, Fang Y, Gu S, Su X, Ding F, Ali WB, Modine T, Zhang R. Percutaneous Ventricular Restoration Prevents Left Ventricular Remodeling Post Myocardial Infarction: One-Year Evaluation of the Heartech First-in-man Study. Journal of Cardiac Failure 2022. [DOI: 10.1016/j.cardfail.2021.10.017] [Reference Citation Analysis]
195 Bartunek J, Terzic A, Davison BA, Behfar A, Sanz-Ruiz R, Wojakowski W, Sherman W, Heyndrickx GR, Metra M, Filippatos GS, Waldman SA, Teerlink JR, Henry TD, Gersh BJ, Hajjar R, Tendera M, Senger S, Cotter G, Povsic TJ, Wijns W; CHART Program. Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. ESC Heart Fail 2020. [PMID: 33094909 DOI: 10.1002/ehf2.13031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
196 Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail 2020;8:329-40. [PMID: 32035892 DOI: 10.1016/j.jchf.2019.12.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 23.5] [Reference Citation Analysis]
197 Gulati G, Udelson JE. Heart Failure With Improved Ejection Fraction: Is it Possible to Escape One's Past? JACC Heart Fail 2018;6:725-33. [PMID: 30098965 DOI: 10.1016/j.jchf.2018.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
198 Lupu A, Lupu S, Agoston-coldea L. Is galectin-3 a promoter of ventricular dysfunction? Revista Romana de Medicina de Laborator 2018;26:21-36. [DOI: 10.2478/rrlm-2018-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, Vila J, Peñafiel J, Urrutia A, Ferrer E, Vallejo N, Januzzi JL, Bayes-genis A. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. International Journal of Cardiology 2015;184:337-43. [DOI: 10.1016/j.ijcard.2015.02.019] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
200 Psotka MA, Gottlieb SS, Francis GS, Allen LA, Teerlink JR, Adams KF, Rosano GM, Lancellotti P. Cardiac Calcitropes, Myotropes, and Mitotropes. Journal of the American College of Cardiology 2019;73:2345-53. [DOI: 10.1016/j.jacc.2019.02.051] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
201 Januzzi JL, Hauptman PJ. Reversed Reverse Remodeling: Can Biomonitoring Solve the Clinical Conundrum of the 3Rs? Circ: Heart Failure 2014;7:388-90. [DOI: 10.1161/circheartfailure.114.001357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
202 Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N; COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 2016;388:2895-903. [PMID: 27914656 DOI: 10.1016/S0140-6736(16)32049-9] [Cited by in Crossref: 141] [Cited by in F6Publishing: 67] [Article Influence: 23.5] [Reference Citation Analysis]
203 Goldberg LR. The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure. J Am Coll Cardiol 2021;77:256-8. [PMID: 33478648 DOI: 10.1016/j.jacc.2020.11.029] [Reference Citation Analysis]
204 Fu H, Chen Q. Mesenchymal stem cell therapy for heart failure: a meta-analysis. Herz 2020;45:557-63. [PMID: 30341444 DOI: 10.1007/s00059-018-4762-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
205 Wang K, Youngson E, Bakal JA, Thomas J, McAlister FA, Oudit GY. Cardiac reverse remodelling and health status in patients with chronic heart failure. ESC Heart Fail 2021;8:3106-18. [PMID: 34002942 DOI: 10.1002/ehf2.13417] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
206 Ambrosy AP, Velazquez EJ. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Am Heart J 2018;199:176-7. [PMID: 29754658 DOI: 10.1016/j.ahj.2018.02.007] [Reference Citation Analysis]
207 Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD; PROVE-HF Investigators. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA 2019;322:1085-95. [PMID: 31475295 DOI: 10.1001/jama.2019.12821] [Cited by in Crossref: 210] [Cited by in F6Publishing: 165] [Article Influence: 70.0] [Reference Citation Analysis]
208 Auricchio A, Schillinger W, Meyer S, Maisano F, Hoffmann R, Ussia GP, Pedrazzini GB, van der Heyden J, Fratini S, Klersy C, Komtebedde J, Franzen O. Correction of Mitral Regurgitation in Nonresponders to Cardiac Resynchronization Therapy by MitraClip Improves Symptoms and Promotes Reverse Remodeling. Journal of the American College of Cardiology 2011;58:2183-9. [DOI: 10.1016/j.jacc.2011.06.061] [Cited by in Crossref: 195] [Cited by in F6Publishing: 132] [Article Influence: 17.7] [Reference Citation Analysis]
209 Safiullina AA, Uskach TM, Dobrovolskaya SV, Saidova MA, Makeev MI, Tereshchenko SN. Reverse remodeling against the background of cardiac contractility modulation therapy in patients with heart failure and atrial fibrillation. Cardiovasc Ther Prev 2022;21:2948. [DOI: 10.15829/1728-8800-2022-2948] [Reference Citation Analysis]
210 Paton MF, Witte KK. Heart failure and right ventricular pacing - how to avoid the need for cardiac resynchronization therapy. Expert Rev Med Devices 2019;16:35-43. [PMID: 30477355 DOI: 10.1080/17434440.2019.1552133] [Reference Citation Analysis]
211 Ramani R, Nilles K, Gibson G, Burkhead B, Mathier M, McNamara D, McTiernan CF. Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci 2011;4:24-31. [PMID: 21348952 DOI: 10.1111/j.1752-8062.2010.00252.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
212 Anker SD, Starling RC, Khan MS, Friede T, Filippatos G, Lindenfeld J, Stephan von Bardeleben R, Coats AJS, Butler J. Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. JACC Heart Fail 2021;9:453-62. [PMID: 33992567 DOI: 10.1016/j.jchf.2021.03.002] [Reference Citation Analysis]
213 Allida S, Du H, Xu X, Prichard R, Chang S, Hickman LD, Davidson PM, Inglis SC. mHealth education interventions in heart failure. Cochrane Database Syst Rev 2020;7:CD011845. [PMID: 32613635 DOI: 10.1002/14651858.CD011845.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
214 Pozo E, Sanz J. Imaging techniques in the evaluation of post-infarction function and scar. Rev Esp Cardiol (Engl Ed) 2014;67:754-64. [PMID: 25172072 DOI: 10.1016/j.rec.2014.04.009] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
215 Muhammed A, Abdelazeem M, Elewa MG, Sharief M, Ammar A. Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction. Heart Fail Rev 2022. [PMID: 35587303 DOI: 10.1007/s10741-022-10246-6] [Reference Citation Analysis]
216 Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98-108. [PMID: 21232712 DOI: 10.1016/j.jcmg.2010.10.008] [Cited by in Crossref: 392] [Cited by in F6Publishing: 347] [Article Influence: 35.6] [Reference Citation Analysis]
217 Linde C, Curtis AB, Fonarow GC, Lee K, Little W, Tang A, Levya F, Momomura S, Manrodt C, Bergemann T, Cowie MR. Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. Int J Cardiol 2016;202:349-55. [PMID: 26426276 DOI: 10.1016/j.ijcard.2015.09.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
218 Rickard J, Baranowski B, Wilson Tang WH, Grimm RA, Niebauer M, Cantillion D, Wilkoff BL, Varma N. Echocardiographic Predictors of Long-Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What Is the Optimal Metric? J Cardiovasc Electrophysiol 2017;28:410-5. [PMID: 28176410 DOI: 10.1111/jce.13175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
219 Tang JN, Cores J, Huang K, Cui XL, Luo L, Zhang JY, Li TS, Qian L, Cheng K. Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future. Stem Cells Transl Med 2018;7:354-9. [PMID: 29468830 DOI: 10.1002/sctm.17-0196] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 15.3] [Reference Citation Analysis]
220 Loforte A, Alfonsi J, Gliozzi G, Folesani G, Fiorentino M, Biffi M, Marinelli G, Di Bartolomeo R, Pacini D. Less invasive ventricular enhancement (LIVE) as potential therapy for ischaemic cardiomyopathy end-stage heart failure. J Thorac Dis 2019;11:S921-8. [PMID: 31183171 DOI: 10.21037/jtd.2019.02.86] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
221 Mick SL, Keshavamurthy S, Gillinov AM. Mitral valve repair versus replacement. Ann Cardiothorac Surg. 2015;4:230-237. [PMID: 26309824 DOI: 10.3978/j.issn.2225-319x.2015.03.01] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
222 Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, Hung JW, Voisine P, Dagenais F, Gillinov AM, Thourani V, Argenziano M, Gammie JS, Mack M, Demers P, Atluri P, Rose EA, O'Sullivan K, Williams DL, Bagiella E, Michler RE, Weisel RD, Miller MA, Geller NL, Taddei-Peters WC, Smith PK, Moquete E, Overbey JR, Kron IL, O'Gara PT, Acker MA; CTSN. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med 2016;374:344-53. [PMID: 26550689 DOI: 10.1056/NEJMoa1512913] [Cited by in Crossref: 461] [Cited by in F6Publishing: 106] [Article Influence: 65.9] [Reference Citation Analysis]
223 Tayal U, Prasad SK. Myocardial remodelling and recovery in dilated cardiomyopathy. JRSM Cardiovasc Dis 2017;6:2048004017734476. [PMID: 29051817 DOI: 10.1177/2048004017734476] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
224 Annamalai SK, Buiten L, Esposito ML, Paruchuri V, Mullin A, Breton C, Pedicini R, O'kelly R, Morine K, Wessler B, Patel AR, Kiernan MS, Karas RH, Kapur NK. Acute Hemodynamic Effects of Intra-aortic Balloon Counterpulsation Pumps in Advanced Heart Failure. Journal of Cardiac Failure 2017;23:606-14. [DOI: 10.1016/j.cardfail.2017.05.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
225 Wan H, Huang T, Zhang H, Wu Q. Effects of Ivabradine on Cardiac Remodeling in Patients With Stable Symptomatic Heart Failure: A Systematic Review and Meta-analysis. Clin Ther 2020;42:2289-2297.e0. [PMID: 33160681 DOI: 10.1016/j.clinthera.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
226 Udelson JE. Left Ventricular Shape: The Forgotten Stepchild of Remodeling Parameters. JACC Heart Fail 2017;5:179-81. [PMID: 28254123 DOI: 10.1016/j.jchf.2017.01.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
227 Poglajen G, Anžič-Drofenik A, Zemljič G, Frljak S, Cerar A, Okrajšek R, Šebeštjen M, Vrtovec B. Long-Term Effects of Angiotensin Receptor-Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction. Diagnostics (Basel) 2020;10:E522. [PMID: 32731353 DOI: 10.3390/diagnostics10080522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
228 Hoshiba Y, Sugimoto A, Doi S, Sawada T, Tamiya S, Ito D, Iseki H. Discontinuation of Cardiac Resynchronization Therapy for Heart Failure Due to Dilated Cardiomyopathy in a 61-Year-Old Female "-Super-Responder" with Return of a Reduced Left Ventricular Ejection Fraction to Normal. Am J Case Rep 2020;21:e926704. [PMID: 32986689 DOI: 10.12659/AJCR.926704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Savarese G, Musella F, D’amore C, Vassallo E, Losco T, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-filardi P. Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure. JACC: Heart Failure 2014;2:148-58. [DOI: 10.1016/j.jchf.2013.11.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
230 Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail 2020;22:2160-71. [PMID: 32985088 DOI: 10.1002/ejhf.2015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
231 Abboud A, Januzzi JL. Reverse Cardiac Remodeling and ARNI Therapy. Curr Heart Fail Rep 2021;18:71-83. [DOI: 10.1007/s11897-021-00501-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
232 Martinez EC, Lilyanna S, Wang P, Vardy LA, Jiang X, Armugam A, Jeyaseelan K, Richards AM. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease. J Mol Cell Cardiol 2017;112:27-39. [PMID: 28865712 DOI: 10.1016/j.yjmcc.2017.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
233 Nair N, Gongora E. Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology? J Circ Biomark 2018;7:1849454417751735. [PMID: 29375722 DOI: 10.1177/1849454417751735] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
234 Kalogeropoulos AP, Georgiopoulou VV, Gheorghiade M, Butler J. Echocardiographic Evaluation of Left Ventricular Structure and Function: New Modalities and Potential Applications in Clinical Trials. Journal of Cardiac Failure 2012;18:159-72. [DOI: 10.1016/j.cardfail.2011.10.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
235 Reinstadler SJ, Feistritzer HJ, Reindl M, Klug G, Mayr A, Mair J, Jaschke W, Metzler B. Combined biomarker testing for the prediction of left ventricular remodelling in ST-elevation myocardial infarction. Open Heart. 2016;3:e000485. [PMID: 27738517 DOI: 10.1136/openhrt-2016-000485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
236 Gierula J, Lowry JE, Paton MF, Cole CA, Byrom R, Koshy AO, Chumun H, Kearney LC, Straw S, Bowen TS, Cubbon RM, Keenan A, Stocken DD, Kearney MT, Witte KK. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study. Circulation 2020;141:1693-703. [DOI: 10.1161/circulationaha.119.045066] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
237 Borow KM, Yaroshinsky A, Greenberg B, Perin EC. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. Circ Res. 2019;125:265-281. [PMID: 31318648 DOI: 10.1161/circresaha.119.314951] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
238 Tardif JC, O'Meara E, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K; SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011;32:2507-15. [PMID: 21875858 DOI: 10.1093/eurheartj/ehr311] [Cited by in Crossref: 198] [Cited by in F6Publishing: 161] [Article Influence: 18.0] [Reference Citation Analysis]
239 Romeo FJ, Seropian IM, Arora S, Vavalle JP, Falconi M, Oberti P, Kotowicz V, Agatiello CR, Berrocal DH. Prognostic impact of myocardial contraction fraction in patients undergoing transcatheter aortic valve replacement for aortic stenosis. Cardiovasc Diagn Ther 2020;10:12-23. [PMID: 32175223 DOI: 10.21037/cdt.2019.05.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
240 Tomasik A, Jacheć W, Wojciechowska C, Kawecki D, Białkowska B, Romuk E, Gabrysiak A, Birkner E, Kalarus Z, Nowalany-Kozielska E. Randomized placebo controlled blinded study to assess valsartan efficacy in preventing left ventricle remodeling in patients with dual chamber pacemaker--Rationale and design of the trial. Contemp Clin Trials 2015;42:239-43. [PMID: 25858003 DOI: 10.1016/j.cct.2015.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Weir-McCall JR, White RD, Ramkumar PG, Gandy SJ, Khan F, Belch JJ, Struthers AD, Houston JG. Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography: a feasibility study. Int J Cardiovasc Imaging 2016;32:825-32. [PMID: 26809611 DOI: 10.1007/s10554-016-0842-z] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
242 Abraham WT. Could the Parachute™ ventricular partitioning device be a winner in the fight against heart failure? Expert Rev Cardiovasc Ther 2013;11:263-5. [PMID: 23469903 DOI: 10.1586/erc.13.12] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
243 Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol 2020;76:719-34. [PMID: 32762907 DOI: 10.1016/j.jacc.2020.05.075] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 31.0] [Reference Citation Analysis]
244 Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation 2021;143:516-25. [PMID: 33186500 DOI: 10.1161/CIRCULATIONAHA.120.052186] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
245 Makkar RR, Kereiakes DJ, Aguirre F, Kowalchuk G, Chakravarty T, Malliaras K, Francis GS, Povsic TJ, Schatz R, Traverse JH, Pogoda JM, Smith RR, Marbán L, Ascheim DD, Ostovaneh MR, Lima JAC, Demaria A, Marbán E, Henry TD. Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. European Heart Journal 2020;41:3451-8. [DOI: 10.1093/eurheartj/ehaa541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
246 Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD, Shea S, Weiss NS, Kronmal RA. Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study. J Am Coll Cardiol 2016;67:1544-52. [PMID: 27150686 DOI: 10.1016/j.jacc.2016.01.045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
247 Ganesananthan S, Shah N, Shah P, Elsayed H, Phillips J, Parkes A, Morgan A, Yousef Z. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart 2020;7:e001305. [PMID: 33020255 DOI: 10.1136/openhrt-2020-001305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
248 Konstam MA, Abboud FM. Ejection Fraction: Misunderstood and Overrated (Changing the Paradigm in Categorizing Heart Failure). Circulation 2017;135:717-9. [PMID: 28223323 DOI: 10.1161/CIRCULATIONAHA.116.025795] [Cited by in Crossref: 104] [Cited by in F6Publishing: 38] [Article Influence: 26.0] [Reference Citation Analysis]
249 Lupu S, Agoston-Coldea L. Soluble ST2 in Ventricular Dysfunction. Adv Clin Chem 2015;69:139-59. [PMID: 25934361 DOI: 10.1016/bs.acc.2014.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
250 Adamo L, Perry A, Novak E, Makan M, Lindman BR, Mann DL. Abnormal Global Longitudinal Strain Predicts Future Deterioration of Left Ventricular Function in Heart Failure Patients With a Recovered Left Ventricular Ejection Fraction. Circ Heart Fail 2017;10:e003788. [PMID: 28559418 DOI: 10.1161/CIRCHEARTFAILURE.116.003788] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
251 Davison BA, Cotter G, Filippatos GS, Zannad F, Voors AA, Metra M, Teerlink JR, Senger S, Mebazaa A, Greenberg B. Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. Heart Fail Rev 2021;26:255-62. [PMID: 32939666 DOI: 10.1007/s10741-020-10020-6] [Reference Citation Analysis]
252 Menicanti L, Castelvecchio S. Left ventricular reconstruction concomitant to coronary artery bypass grafting: when and how? Current Opinion in Cardiology 2011;26:523-7. [DOI: 10.1097/hco.0b013e32834ba1cc] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
253 Reis Filho JR, Cardoso JN, Cardoso CM, Pereira-Barretto AC. Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure. Arq Bras Cardiol 2015;104:502-6. [PMID: 26131706 DOI: 10.5935/abc.20150025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
254 Nwabuo CC, Moreira HT, Vasconcellos HD, Mewton N, Opdahl A, Ogunyankin KO, Ambale-Venkatesh B, Schreiner PJ, Armstrong AAC, Lewis CE, Jacobs DR, Lloyd-Jones D, Gidding SS, Lima JAC. Left ventricular global function index predicts incident heart failure and cardiovascular disease in young adults: the coronary artery risk development in young adults (CARDIA) study. Eur Heart J Cardiovasc Imaging 2019;20:533-40. [PMID: 30247530 DOI: 10.1093/ehjci/jey123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]